Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1992 Sep;55(9):758–761. doi: 10.1136/jnnp.55.9.758

Effect of vigabatrin on striatal dopamine receptors: evidence in humans for interactions of GABA and dopamine systems.

H A Ring 1, M R Trimble 1, D C Costa 1, M S George 1, P Verhoeff 1, P J Ell 1
PMCID: PMC1015097  PMID: 1328538

Abstract

Vigabatrin is a specific gamma-aminobutyric acid transaminase inhibitor. The clinical use of this drug in the treatment of epilepsy has been sporadically linked to the development of psychosis. Using 123I-IBZM, a specific dopamine D2 receptor ligand and single photon emission tomography (SPET), one month of treatment with vigabatrin was associated with a decrease in specific binding of 123I-IBZM to D2 receptors in the left hemisphere basal ganglia. This change may provide one explanation for the development of psychosis in vulnerable patients.

Full text

PDF
758

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ben-Menachem E., Persson L. I., Schechter P. J., Haegele K. D., Huebert N., Hardenberg J., Dahlgren L., Mumford J. P. The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients. Br J Clin Pharmacol. 1989;27 (Suppl 1):79S–85S. doi: 10.1111/j.1365-2125.1989.tb03466.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bland J. M., Altman D. G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986 Feb 8;1(8476):307–310. [PubMed] [Google Scholar]
  3. Brücke T., Podreka I., Angelberger P., Wenger S., Topitz A., Küfferle B., Müller C., Deecke L. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab. 1991 Mar;11(2):220–228. doi: 10.1038/jcbfm.1991.53. [DOI] [PubMed] [Google Scholar]
  4. Costa D. C., Verhoeff N. P., Cullum I. D., Ell P. J., Syed G. M., Barrett J., Palazidou E., Toone B., Van Royen E., Bobeldijk M. In vivo characterisation of 3-iodo-6-methoxybenzamide 123I in humans. Eur J Nucl Med. 1990;16(11):813–816. doi: 10.1007/BF00833017. [DOI] [PubMed] [Google Scholar]
  5. Farde L., Ehrin E., Eriksson L., Greitz T., Hall H., Hedström C. G., Litton J. E., Sedvall G. Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. Proc Natl Acad Sci U S A. 1985 Jun;82(11):3863–3867. doi: 10.1073/pnas.82.11.3863. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Farde L., Hall H., Ehrin E., Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science. 1986 Jan 17;231(4735):258–261. doi: 10.1126/science.2867601. [DOI] [PubMed] [Google Scholar]
  7. Galloway M. P. Neurochemical interactions of cocaine with dopaminergic systems. Trends Pharmacol Sci. 1988 Dec;9(12):451–454. doi: 10.1016/0165-6147(88)90137-x. [DOI] [PubMed] [Google Scholar]
  8. Grace A. A., Bunney B. S. Opposing effects of striatonigral feedback pathways on midbrain dopamine cell activity. Brain Res. 1985 May 6;333(2):271–284. doi: 10.1016/0006-8993(85)91581-1. [DOI] [PubMed] [Google Scholar]
  9. Iadarola M. J., Gale K. Substantia nigra: site of anticonvulsant activity mediated by gamma-aminobutyric acid. Science. 1982 Dec 17;218(4578):1237–1240. doi: 10.1126/science.7146907. [DOI] [PubMed] [Google Scholar]
  10. Jung M. J., Lippert B., Metcalf B. W., Böhlen P., Schechter P. J. gamma-Vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. J Neurochem. 1977 Nov;29(5):797–802. doi: 10.1111/j.1471-4159.1977.tb10721.x. [DOI] [PubMed] [Google Scholar]
  11. Kung H. F., Alavi A., Chang W., Kung M. P., Keyes J. W., Jr, Velchik M. G., Billings J., Pan S., Noto R., Rausch In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans. J Nucl Med. 1990 May;31(5):573–579. [PubMed] [Google Scholar]
  12. Kung H. F., Pan S., Kung M. P., Billings J., Kasliwal R., Reilley J., Alavi A. In vitro and in vivo evaluation of [123I]IBZM: a potential CNS D-2 dopamine receptor imaging agent. J Nucl Med. 1989 Jan;30(1):88–92. [PubMed] [Google Scholar]
  13. Lippert B., Metcalf B. W., Jung M. J., Casara P. 4-amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric-acid aminotransferase in mammalian brain. Eur J Biochem. 1977 Apr 15;74(3):441–445. doi: 10.1111/j.1432-1033.1977.tb11410.x. [DOI] [PubMed] [Google Scholar]
  14. Maxwell D. J., Fyffe R. E., Rethelyi M. Morphological properties of physiologically characterized lamina III neurones in the cat spinal cord. Neuroscience. 1983 Sep;10(1):1–22. doi: 10.1016/0306-4522(83)90076-3. [DOI] [PubMed] [Google Scholar]
  15. Riekkinen P. J., Pitkanen A., Ylinen A., Sivenius J., Halonen T. Specificity of vigabatrin for the GABAergic system in human epilepsy. Epilepsia. 1989;30 (Suppl 3):S18–S22. doi: 10.1111/j.1528-1157.1989.tb05828.x. [DOI] [PubMed] [Google Scholar]
  16. Sander J. W., Hart Y. M., Trimble M. R., Shorvon S. D. Vigabatrin and psychosis. J Neurol Neurosurg Psychiatry. 1991 May;54(5):435–439. doi: 10.1136/jnnp.54.5.435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Schechter P. J., Hanke N. F., Grove J., Huebert N., Sjoerdsma A. Biochemical and clinical effects of gamma-vinyl GABA in patients with epilepsy. Neurology. 1984 Feb;34(2):182–186. doi: 10.1212/wnl.34.2.182. [DOI] [PubMed] [Google Scholar]
  18. Singhaniyom W., Tsai Y. F., Brücke T., McLellan C. A., Cohen R. M., Kung H. F., Chiueh C. C. Blockade of in vivo binding of 125I-labeled 3-iodobenzamide (IBZM) to dopamine receptors by D2 antagonist and agonist. Brain Res. 1988 Jun 21;453(1-2):393–396. doi: 10.1016/0006-8993(88)90186-2. [DOI] [PubMed] [Google Scholar]
  19. Volkow N. D., Fowler J. S., Wolf A. P., Schlyer D., Shiue C. Y., Alpert R., Dewey S. L., Logan J., Bendriem B., Christman D. Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry. 1990 Jun;147(6):719–724. doi: 10.1176/ajp.147.6.719. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES